Affronti, M. L., Friedman, H. S., Desjardins, A., Vlahovic, G., Randazzo, D. M., Herndon, J. E., . . . Peters, K. B. (2015). ATCT-01 PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RILOTUMUMAB AND BEVACIZUMAB (BEV) IN SUBJECTS WITH RECURRENT MALIGNANT GLIOMA (MG). Neuro Oncol.
Citação norma ChicagoAffronti, Mary L., et al. "ATCT-01 PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RILOTUMUMAB AND BEVACIZUMAB (BEV) IN SUBJECTS WITH RECURRENT MALIGNANT GLIOMA (MG)." Neuro Oncol 2015.
Citação norma MLAAffronti, Mary L., et al. "ATCT-01 PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RILOTUMUMAB AND BEVACIZUMAB (BEV) IN SUBJECTS WITH RECURRENT MALIGNANT GLIOMA (MG)." Neuro Oncol 2015.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.